Polo-like Kinase 2 (PLK2) Phosphorylates α-Synuclein at Serine 129 in Central Nervous System*S⃞

Several neurological diseases, including Parkinson disease and dementia with Lewy bodies, are characterized by the accumulation of α-synuclein phosphorylated at Ser-129 (p-Ser-129). The kinase or kinases responsible for this phosphorylation have been the subject of intense investigation. Here we submit evidence that polo-like kinase 2 (PLK2, also known as serum-inducible kinase or SNK) is a principle contributor to α-synuclein phosphorylation at Ser-129 in neurons. PLK2 directly phosphorylates α-synuclein at Ser-129 in an in vitro biochemical assay. Inhibitors of PLK kinases inhibited α-synuclein phosphorylation both in primary cortical cell cultures and in mouse brain in vivo. Finally, specific knockdown of PLK2 expression by transduction with short hairpin RNA constructs or by knock-out of the plk2 gene reduced p-Ser-129 levels. These results indicate that PLK2 plays a critical role in α-synuclein phosphorylation in central nervous system.

[1]  Olaf Riess,et al.  AlaSOPro mutation in the gene encoding α-synuclein in Parkinson's disease , 1998, Nature Genetics.

[2]  Péter Lénárt,et al.  BI 2536, a Potent and Selective Inhibitor of Polo-like Kinase 1, Inhibits Tumor Growth In Vivo , 2007, Current Biology.

[3]  M. Feany,et al.  α-Synuclein phosphorylation controls neurotoxicity and inclusion formation in a Drosophila model of Parkinson disease , 2005, Nature Neuroscience.

[4]  Philippe Amouyel,et al.  α-synuclein locus duplication as a cause of familial Parkinson's disease , 2004, The Lancet.

[5]  E. Masliah,et al.  α-Synuclein is phosphorylated in synucleinopathy lesions , 2002, Nature Cell Biology.

[6]  Hideo Fujiwara,et al.  Hyperphosphorylation and insolubility of α‐synuclein in transgenic mouse oligodendrocytes , 2002 .

[7]  Specificity and Regulation of Casein Kinase-Mediated Phosphorylation of &agr;-Synuclein , 2008 .

[8]  J. Benovic,et al.  Synucleins Are a Novel Class of Substrates for G Protein-coupled Receptor Kinases* , 2000, The Journal of Biological Chemistry.

[9]  Hamid Mirzaei,et al.  Identification of rotenone-induced modifications in alpha-synuclein using affinity pull-down and tandem mass spectrometry. , 2006, Analytical chemistry.

[10]  M. Sheng,et al.  Targeted Protein Degradation and Synapse Remodeling by an Inducible Protein Kinase , 2003, Science.

[11]  Robert L. Nussbaum,et al.  Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease , 1997 .

[12]  W. Spooren,et al.  Age-dependent cognitive decline and amygdala pathology in α-synuclein transgenic mice , 2007, Neurobiology of Aging.

[13]  R. Mandel,et al.  The phosphorylation state of Ser-129 in human α-synuclein determines neurodegeneration in a rat model of Parkinson disease , 2008, Proceedings of the National Academy of Sciences.

[14]  Eric F. Johnson,et al.  Pharmacological and functional comparison of the polo-like kinase family: insight into inhibitor and substrate specificity. , 2007, Biochemistry.

[15]  R. Barbour,et al.  Phosphorylation of Ser-129 Is the Dominant Pathological Modification of α-Synuclein in Familial and Sporadic Lewy Body Disease* , 2006, Journal of Biological Chemistry.

[16]  M. Sheng,et al.  Activity-Induced Polo-Like Kinase 2 Is Required for Homeostatic Plasticity of Hippocampal Neurons during Epileptiform Activity , 2008, The Journal of Neuroscience.

[17]  A Dürr,et al.  Causal relation between α-synuclein locus duplication as a cause of familial Parkinson's disease , 2004, The Lancet.

[18]  L. Meijer,et al.  Constitutive Phosphorylation of the Parkinson's Disease Associated α-Synuclein* , 2000, The Journal of Biological Chemistry.

[19]  J. Charron,et al.  Role of Plk2 (Snk) in Mouse Development and Cell Proliferation , 2003, Molecular and Cellular Biology.

[20]  P. Lansbury,et al.  Phosphorylation at Ser-129 but Not the Phosphomimics S129E/D Inhibits the Fibrillation of α-Synuclein* , 2008, Journal of Biological Chemistry.

[21]  F. Gage,et al.  Neprilysin regulates amyloid β peptide levels , 2007, Journal of Molecular Neuroscience.

[22]  M. Sheng,et al.  Critical Role of CDK5 and Polo-like Kinase 2 in Homeostatic Synaptic Plasticity during Elevated Activity , 2008, Neuron.

[23]  R. Nussbaum,et al.  α-Synuclein Is Phosphorylated by Members of the Src Family of Protein-tyrosine Kinases* , 2001, The Journal of Biological Chemistry.

[24]  M. L. Schmidt,et al.  α-Synuclein in Lewy bodies , 1997, Nature.

[25]  J Q Trojanowski,et al.  Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies. , 1998, The American journal of pathology.

[26]  U. Staubli,et al.  The polo‐like protein kinases Fnk and Snk associate with a Ca2+‐ and integrin‐binding protein and are regulated dynamically with synaptic plasticity , 1999, The EMBO journal.

[27]  J. Hoenicka,et al.  The new mutation, E46K, of α‐synuclein causes parkinson and Lewy body dementia , 2004, Annals of neurology.

[28]  D. Mann,et al.  Casein kinase 2 is the major enzyme in brain that phosphorylates Ser129 of human α‐synuclein: Implication for α‐synucleinopathies , 2007 .

[29]  Janel O. Johnson,et al.  α-Synuclein Locus Triplication Causes Parkinson's Disease , 2003, Science.

[30]  R. Rydel,et al.  α2β1 and αVβ1 integrin signaling pathways mediate amyloid-β-induced neurotoxicity , 2007, Neurobiology of Aging.

[31]  R. Crowther,et al.  α-Synuclein in filamentous inclusions of Lewy bodies from Parkinson’s disease and dementia with Lewy bodies , 1998 .